4-(4-甲基-1,4-二氮杂环庚烷-1-基)苯甲腈 | 166438-80-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(4-甲基-1,4-二氮杂环庚烷-1-基)苯甲腈
• 英文名称: 4-methyl-1-(4-cyanophenyl)-homopiperazine
• 英文别名: 4-(4-Methyl-1,4-diazepan-1-yl)benzonitrile；4-(4-methylhomopiperazin-1-yl)benzonitrile
• CAS: 166438-80-8
• 化学式: C₁₃H₁₇N₃
• mdl: MFCD08690317
• 分子量: 215.298
• InChiKey: LWRMQRYMWJWCLS-UHFFFAOYSA-N

物化性质

• 熔点：
  92.5-94.5
• 沸点：
  371.5±37.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  30.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  C

反应信息

• 作为反应物：
  描述：

  4-(4-甲基-1,4-二氮杂环庚烷-1-基)苯甲腈 在 吡啶 、 sodium hydroxide 、 氯化亚砜 作用下， 反应 62.0h， 生成 ethyl 3-[(3-cyanophenoxy)methyl]-4-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzoate
  参考文献：
  名称：

  Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors

  摘要：

  Factor Xa (fXa) is a serine protease that plays a pivotal role in the coagulation cascade. High-tbroughput screening of the Yamanouchi compound library yielded lead compound I with the ability to inhibit fXa at micromolar concentrations. To improve its fXa inhibitory activity and its oral anticoagulant activity, the linker between benzamidine and the central benzene ring was modified and a carboxyl group was introduced at the central benzene ring. The resulting compounds 40b (YM-203552), 41a (YM-202054), and 41c (YM-203558) exhibited potent fXa inhibitory activity and oral anticoagulant activity. In particular, YM-203558 exhibited the most potent oral anticoagulant activity, prolonging PT more than 3-fold at 0.5 and 2.0h. Additionally, these compounds showed a high degree of selectivity for other serine proteases. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.11.005
• 作为产物：
  描述：

  4-(六氢-4-甲基-1H-1,4-二氮杂卓-1-基)-苯甲醇 在 ammonium hydroxide 作用下， 以 叔丁醇 为溶剂， 120.0 ℃ 、1.0 MPa 条件下， 反应 24.0h， 以80%的产率得到4-(4-甲基-1,4-二氮杂环庚烷-1-基)苯甲腈
  参考文献：
  名称：

  用于有氧氧化合成（杂）芳香醛、酮、酯、酸、腈和酰胺的“通用”催化剂

  摘要：

  功能化（杂）芳族化合物是基础和应用科学中广泛使用的不可或缺的化学品。其中，尤其是芳香醛、酮、羧酸、酯、腈和酰胺是有价值的精细和大宗化学品，可用于化学、制药、农业化学和材料工业。对于它们的合成，醇的催化有氧氧化构成了一种绿色、可持续且具有成本效益的工艺，理想情况下应该利用活性和选择性的 3D 金属。在这里，我们报告了通过在碳上热解钴-哌嗪-酒石酸络合物作为最通用的氧化催化剂，制备包裹在 Co-纳米颗粒中的石墨层。这种独特的材料可以合成简单、功能化和结构多样的（杂）芳香醛、酮、

  DOI：

  10.1016/j.chempr.2021.12.001
• 作为试剂：
  描述：

  对氟苯腈 、 N-甲基高哌嗪 、 N,N-二甲基甲酰胺 在 乙酸乙酯 、 水 、 magnesium sulfate 、 silica gel 、 methanol-dichloromethane 、 4-(4-甲基-1,4-二氮杂环庚烷-1-基)苯甲腈 、 硫酸 、 ice 作用下， 反应 54.0h， 以4-(4-Methyl[1,4]diazepan-1-yl)benzamide (3.7 g, 38%) is thus obtained in the form of a yellow solid, which的产率得到4-(4-Methyl[1,4]diazepan-1-yl)benzamide
  参考文献：
  名称：

  Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof

  摘要：

  本发明涉及式(I)的肼氨基羰基噻吩[2,3-c]吡唑化合物：其中R1、R3、R4和R5如本文所定义；它们的制备方法、含有它们的组合物以及它们作为治疗病理状况，特别是作为抗癌剂的用途。

  公开号：

  US20080146542A1

文献信息

• Npy antagonists, preparation and uses
  申请人：Botez Iuliana

  公开号：US20090233910A1

  公开（公告）日：2009-09-17

  The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

  本发明涉及新颖化合物，它们的制备和用途，特别是在治疗方面的用途。更具体地说，它涉及至少具有两个芳香环的衍生化合物，它们的制备和用途，特别是在人类或动物健康领域。这些化合物对存在于中枢和外周神经系统中的神经肽Y（NPY）的生物受体具有亲和力。本发明的化合物优选为NPY拮抗剂，更具体地说是NPY Y1亚型的拮抗剂，因此可用于治疗或预防涉及NPY的任何疾病。本发明还涉及含有所述化合物的药物组合物，其制备和用途，以及使用所述化合物的治疗方法。
• Imidazole derivatives
  申请人：Welfide Corporation

  公开号：US06288061B1

  公开（公告）日：2001-09-11

  The present invention relates to the imidazole derivative of the following formula (I) wherein R1 is hydrogen, optionally substituted alkyl and the like, R2 is hydrogen, optionally substituted alkyl and the like, R3is optionally substituted heteroaryl, R4 is optionally substituted cycloalkyl, optionally substituted phenyl and the like, provided that when R1 is hydrogen, and R2 and R4 are the same or different and each is phenyl or phenyl substituted by halogen atom, lower alkyl or lower alkoxy, R3 is benzothiazolyl or thiazolyl substituted by phenyl, the imidazole derivative of the following formula (XII) wherein R6 is optionally substituted phenyl or optionally substituted heteroaryl and R7 is substituted phenyl, and pharmaceutically acceptable salts thereof. The compounds of the formulas (I) and (XII) and pharmaceutically acceptable salts thereof of the present invention inhibit IL-4 and IL-5 production by Th2 cells and are effective for the prophylaxis and treatment of allergic diseases such as atopic dermatitis, bronchial asthma, allergic rhinitis and the like.

  本发明涉及以下式（I）的咪唑衍生物 其中R1是氢，可选择地取代的烷基等，R2是氢，可选择地取代的烷基等，R3是可选择地取代的杂芳基，R4是可选择地取代的环烷基，可选择地取代的苯基等，但当R1是氢，且R2和R4相同或不同，且每个是苯基或被卤原子、较低烷基或较低烷氧基取代的苯基时，R3是苯并噻唑基或被苯基取代的噻唑基，以下式（XII）的咪唑衍生物 其中R6是可选择地取代的苯基或可选择地取代的杂芳基，R7是被取代的苯基，以及其药学上可接受的盐。本发明的式（I）和（XII）的化合物及其药学上可接受的盐通过抑制Th2细胞产生IL-4和IL-5，在预防和治疗特应性皮炎、支气管哮喘、过敏性鼻炎等过敏性疾病方面具有有效性。
• Diazepane derivatives or salts thereof
  申请人：——

  公开号：US20030195193A1

  公开（公告）日：2003-10-16

  To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-methyl-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4′methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.

  提供一种基于抑制活化的血液凝血因子X而具有抗凝作用的化合物，可用作抗凝剂或预防和治疗由血栓或栓塞引起的疾病的药物。4-[(3-羧基胍基苯基氨基)甲基]-3-[4-(4-甲基-1,4-二氮杂环庚烷-1-基)苯甲酰氨基]苯甲酸和3-羟基-4′-甲氧基-2-{[4-(4-甲基-1,4-二氮杂环庚烷-1-基)苯甲酰]氨基}苯甲酰胺或其盐是有效成分。
• [EN] METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER<br/>[FR] MÉTHODE D'UTILISATION DE COMPOSÉS D'HOMOPIPÉRAZINIUM DANS LE TRAITEMENT DU CANCER
  申请人：UNIVERSITÉ LAVAL

  公开号：WO2015149178A1

  公开（公告）日：2015-10-08

  The present disclosure relates to a method for treating cancer comprising administering to a patient in need thereof an effective amount of a compound having the formula: (Formula (I)) wherein R1, R2, Ya, Xa, and J- are as defined herein.

  本公开涉及一种治疗癌症的方法，包括向有需要的患者施用具有以下化学式的化合物的有效量：（化学式（I）），其中R1、R2、Ya、Xa和J-如本文所定义。
• METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER
  申请人：UNIVERSITÉ LAVAL

  公开号：US20180235978A1

  公开（公告）日：2018-08-23

  A method for treating cancer including administering to a patient in need thereof an effective amount of a compound having the formula: wherein R 1 , R 2 , Ya, Xa, and J − are as defined herein, and may be where R1 and R2 are independently selected from methyl, ethyl, n-propyl, or i-propyl; Xa is N or CH; Ya is hydrogen or independently selected from halogen, cyano, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, heteroaryl of 6 members and aryl; n is 1 or 2; wherein J − is fluoride, chloride, bromide, iodide, acetate, sulfate or sulfonate such as tosylate, mesylate, besylate.

  一种治疗癌症的方法，包括向需要治疗的患者施用具有以下式子的化合物的有效量：其中R1、R2、Ya、Xa和J−的定义如下，可以是R1和R2分别选自甲基、乙基、正丙基或异丙基；Xa为N或CH；Ya为氢或独立选自卤素、氰基、羟基、1到6个碳原子的烷基、1到6个碳原子的烷氧基、6个成员的杂环芳基和芳基；n为1或2；其中J−为氟化物、氯化物、溴化物、碘化物、醋酸盐、硫酸盐或磺酸盐，例如对甲苯磺酸盐、甲磺酸盐、苯磺酸盐。